Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study.

1996205 citationsJournal Article

Authors

Bernard F. Cole · Brown University

Richard D. Gelber · Brown University

J M Kirkwood · Brown University

Aron Goldhirsch · Brown University

Edward Barylak · Brown University

Ernest C. Borden · Brown University

Abstract

For patients with high-risk melanoma, the clinical benefits of high-dose IFN alpha 2b can offset the toxic effects. The optimal treatment for an individual patient depends on the patient's tumor burden and preferences regarding toxicity and disease relapse.

Topics & Keywords

Health Systems, Economic Evaluations, Quality of Life Cutaneous Melanoma Detection and Management CAR-T cell therapy research

Publication Details

Published in: Journal of Clinical Oncology

Volume 14, Issue 10, pp. 2666-2673

DOI: 10.1200/jco.1996.14.10.2666

Field-Weighted Citation Impact: 42.71

Command Palette

Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study.

Authors

Abstract

Topics & Keywords

Publication Details